Cost-effectiveness analysis of drug-eluting beads and conventional transarterial chemoembolization in the treatment of hepatocellular carcinoma
文献类型：期刊论文
| 作者 | Shao, Guoliang1,2; Wang, Jingwen3; Zhou, Xiaoying3; Sun, Guojun3; Dong, Zuojun3 |
| 刊名 | FRONTIERS IN PUBLIC HEALTH
 |
| 出版日期 | 2022-10-26 |
| 卷号 | 10 |
| 关键词 | DEB-TACE cTACE partition survival model cost-effectiveness analysis hepatocellular carcinoma |
| DOI | 10.3389/fpubh.2022.963058 |
| 通讯作者 | Dong, Zuojun(jzd1970@zjut.edu.cn) |
| 英文摘要 | ObjectiveTo conduct a cost-effectiveness analysis of drug-eluting beads transcatheter arterial chemoembolization (DEB-TACE) and conventional transcatheter arterial chemoembolization (cTACE) for first-line treatment of hepatocellular carcinoma (HCC) from the perspective of the Chinese healthcare system. MethodsBased on the real-world clinical data of HCC patients receiving interventional therapy, a partitioned survival model was constructed for cost-effectiveness analysis. The model period is 1 month, and the research time limit is 10 years. The incremental cost-effectiveness ratio (ICER) is used as the evaluation index. One-way sensitivity analysis and probabilistic sensitivity analysis were used to analyze the uncertainty of parameters to test the stability of the model results. ResultsThe ICER of the DEB-TACE group was 11,875.62 $/QALYs, which was lower than the willingness to pay threshold (WTP) of 31,499.23 $/QALYs. One-way sensitivity analysis suggested that the utility value of progression-free survival (PFS) in the DEB-TACE group had the greatest impact. Probabilistic sensitivity analysis showed that at the level of WTP of 31,499.23 $/QALYs, DEB-TACE had a cost-effective probability of 92%. ConclusionUnder the current economic level in my country, DEB-TACE is more cost-effective than cTACE in the treatment of HCC patients. |
| WOS关键词 | CANCER STATISTICS ; SURVIVAL ; CHINA |
| 资助项目 | National Natural Science Foundation of China ; [82072032] |
| WOS研究方向 | Public, Environmental & Occupational Health |
| 语种 | 英语 |
| 出版者 | FRONTIERS MEDIA SA |
| WOS记录号 | WOS:000882370600001 |
| 资助机构 | National Natural Science Foundation of China |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/130425]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 通讯作者 | Dong, Zuojun |
| 作者单位 | 1.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Intervent Therapy, Canc Hosp, Hangzhou, Peoples R China 2.Zhejiang Univ, Precis Innovat Ctr Diag & Treatment Hepatobiliary, Hangzhou, Peoples R China 3.Zhejiang Univ Technol, Coll Pharmaceut Sci, Hangzhou, Peoples R China |
| 推荐引用方式 GB/T 7714 | Shao, Guoliang,Wang, Jingwen,Zhou, Xiaoying,et al. Cost-effectiveness analysis of drug-eluting beads and conventional transarterial chemoembolization in the treatment of hepatocellular carcinoma[J]. FRONTIERS IN PUBLIC HEALTH,2022,10. |
| APA | Shao, Guoliang,Wang, Jingwen,Zhou, Xiaoying,Sun, Guojun,&Dong, Zuojun.(2022).Cost-effectiveness analysis of drug-eluting beads and conventional transarterial chemoembolization in the treatment of hepatocellular carcinoma.FRONTIERS IN PUBLIC HEALTH,10. |
| MLA | Shao, Guoliang,et al."Cost-effectiveness analysis of drug-eluting beads and conventional transarterial chemoembolization in the treatment of hepatocellular carcinoma".FRONTIERS IN PUBLIC HEALTH 10(2022). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。